# A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability

> **NCT01404117** · PHASE2 · WITHDRAWN · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.**

## Conditions studied

- Relapsing Multiple Sclerosis

## Interventions

- **DRUG:** Laquinimod 0.6
- **DRUG:** Laquinimod 1.2
- **OTHER:** Glatiramer Acetate or interferon-beta+ Placebo

## Key facts

- **NCT ID:** NCT01404117
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-03
- **Primary completion:** 2013-12
- **Final completion:** 2014-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study is being redesigned
- **Last updated:** 2013-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01404117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01404117, "A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01404117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*